AnaptysBio, Inc. (ANAB) vs Novavax, Inc. (NVAX)
- AnaptysBio, Inc. ANAB 45.61 −0.26%
- Novavax, Inc. NVAX 7.95 −1.36%
AnaptysBio, Inc. and Novavax, Inc. are both Biotechnology companies. AnaptysBio, Inc. and Novavax, Inc. are of similar size ($1.4B and $1.3B). Novavax, Inc. has negative trailing earnings, so its P/E is not meaningful; AnaptysBio, Inc. trades at 73.6×. AnaptysBio, Inc. grew revenue faster over the last twelve months: 95.2% against −61.3%. AnaptysBio, Inc. has the higher net margin (6.54% vs −18.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, AnaptysBio, Inc. leads on 11 and Novavax, Inc. on 5.
Valuation
Profitability
| Metric | ANAB | NVAX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 78.01% | 70.18% |
| Operating margin | 36.14% | (21.23%) | 0.00% |
| Net margin | 6.54% | (18.64%) | 0.00% |
| Free cash flow margin | 0.00% | (59.25%) | 0.00% |
| Return on equity | (365.73%) | 41.08% | (50.72%) |
| Return on assets | 4.76% | (7.42%) | (45.56%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack